{"id":816,"date":"2024-08-07T21:31:04","date_gmt":"2024-08-07T13:31:04","guid":{"rendered":"https:\/\/flcube.com\/?p=816"},"modified":"2024-10-14T09:43:36","modified_gmt":"2024-10-14T01:43:36","slug":"cloudbreak-pharma-partners-with-santen-pharmaceutical-for-cbt-001-commercialization-in-southeast-asia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=816","title":{"rendered":"Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia"},"content":{"rendered":"\n<p>Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese pharmaceutical firm Santen Pharmaceutical. The collaboration focuses on the development, manufacturing, and commercialization of Cloudbreak&#8217;s investigational drug, CBT-001, across Southeast Asia, including key markets such as Japan, Korea, Vietnam, Thailand, Malaysia, the Philippines, Singapore, and Indonesia. As per the terms of the agreement, Cloudbreak Pharma is set to receive an upfront payment and potential milestone payments totaling up to USD 91 million, in addition to a double-digit percentage of future net sales as royalties.<\/p>\n\n\n\n<p>CBT-001 is an innovative emulsified nintedanib, a multi-kinase inhibitor that targets VEGF (vascular endothelial growth factor), PDGF (platelet-derived growth factor), and FGF (fibroblast growth factor) receptors. The drug is designed to inhibit angiogenesis and fibrosis, making it a potential treatment for pterygium. CBT-001 is currently undergoing a global, multi-center Phase III study in the U.S., China, Australia, New Zealand, and India, following the successful completion of a Phase II study in the U.S.<\/p>\n\n\n\n<p>Pterygium, a non-malignant abnormal proliferation of fibrous vascular tissue on the ocular surface, originates from the conjunctiva and can extend to the corneal surface. Despite its prevalence, there are currently no approved drugs for the treatment of pterygium on the market. The standard of care typically involves the use of artificial tears and short-term topical eye steroids, which have not been specifically clinically approved for this condition.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[414,44,415],"class_list":["post-816","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cloudbreak-pharma","tag-ophthalmology","tag-santen-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese pharmaceutical firm Santen Pharmaceutical. The collaboration focuses on the development, manufacturing, and commercialization of Cloudbreak&#039;s investigational drug, CBT-001, across Southeast Asia, including key markets such as Japan, Korea, Vietnam, Thailand, Malaysia, the Philippines, Singapore, and Indonesia. As per the terms of the agreement, Cloudbreak Pharma is set to receive an upfront payment and potential milestone payments totaling up to USD 91 million, in addition to a double-digit percentage of future net sales as royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=816\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=816\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-07T13:31:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-14T01:43:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=816#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=816\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia\",\"datePublished\":\"2024-08-07T13:31:04+00:00\",\"dateModified\":\"2024-10-14T01:43:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=816\"},\"wordCount\":248,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cloudbreak Pharma\",\"Ophthalmology\",\"Santen Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=816#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=816\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=816\",\"name\":\"Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-08-07T13:31:04+00:00\",\"dateModified\":\"2024-10-14T01:43:36+00:00\",\"description\":\"Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese pharmaceutical firm Santen Pharmaceutical. The collaboration focuses on the development, manufacturing, and commercialization of Cloudbreak's investigational drug, CBT-001, across Southeast Asia, including key markets such as Japan, Korea, Vietnam, Thailand, Malaysia, the Philippines, Singapore, and Indonesia. As per the terms of the agreement, Cloudbreak Pharma is set to receive an upfront payment and potential milestone payments totaling up to USD 91 million, in addition to a double-digit percentage of future net sales as royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=816#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=816\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=816#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia - Insight, China&#039;s Pharmaceutical Industry","description":"Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese pharmaceutical firm Santen Pharmaceutical. The collaboration focuses on the development, manufacturing, and commercialization of Cloudbreak's investigational drug, CBT-001, across Southeast Asia, including key markets such as Japan, Korea, Vietnam, Thailand, Malaysia, the Philippines, Singapore, and Indonesia. As per the terms of the agreement, Cloudbreak Pharma is set to receive an upfront payment and potential milestone payments totaling up to USD 91 million, in addition to a double-digit percentage of future net sales as royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=816","og_locale":"en_US","og_type":"article","og_title":"Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=816","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-08-07T13:31:04+00:00","article_modified_time":"2024-10-14T01:43:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=816#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=816"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia","datePublished":"2024-08-07T13:31:04+00:00","dateModified":"2024-10-14T01:43:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=816"},"wordCount":248,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cloudbreak Pharma","Ophthalmology","Santen Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=816#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=816","url":"https:\/\/flcube.com\/?p=816","name":"Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-08-07T13:31:04+00:00","dateModified":"2024-10-14T01:43:36+00:00","description":"Cloudbreak Pharma Inc., a U.S.-based biopharmaceutical company, has entered into a strategic partnership with Japanese pharmaceutical firm Santen Pharmaceutical. The collaboration focuses on the development, manufacturing, and commercialization of Cloudbreak's investigational drug, CBT-001, across Southeast Asia, including key markets such as Japan, Korea, Vietnam, Thailand, Malaysia, the Philippines, Singapore, and Indonesia. As per the terms of the agreement, Cloudbreak Pharma is set to receive an upfront payment and potential milestone payments totaling up to USD 91 million, in addition to a double-digit percentage of future net sales as royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=816#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=816"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=816#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Cloudbreak Pharma Partners with Santen Pharmaceutical for CBT-001 Commercialization in Southeast Asia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=816"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/816\/revisions"}],"predecessor-version":[{"id":6309,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/816\/revisions\/6309"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}